Journal
SCIENCE
Volume 359, Issue 6378, Pages 926-+Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aar3247
Keywords
-
Categories
Funding
- Lustgarten Foundation for Pancreatic Cancer Research
- Virginia and D. K. Ludwig Fund for Cancer Research
- Conrad N. Hilton Foundation
- Commonwealth Fund
- John Templeton Foundation
- Clinomics Program
- Mayo Clinic Center for Individualized Medicine
- Mayo Clinic Biobank
- Sol Goldman Center for Pancreatic Cancer Research
- Michael Rolfe Pancreatic Cancer Research Foundation
- Benjamin Baker Scholarship
- Gray Foundation
- Marcus Foundation
- Honorable Tina Brozman Foundation
- Burroughs Wellcome Career Award for Medical Scientists
- Doris Duke Charitable Foundation [2014107]
- National Institutes of Health [P50-CA62924, P50-CA102701, CA06973, CA152753, GM-07309, U01CA200469, U01CA152753]
Ask authors/readers for more resources
Earlier detection is key to reducing cancer deaths. Here, we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, to 1005 patients with nonmetastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive in a median of 70% of the eight cancer types. The sensitivities ranged from 69 to 98% for the detection of five cancer types (ovary, liver, stomach, pancreas, and esophagus) for which there are no screening tests available for average-risk individuals. The specificity of CancerSEEK was greater than 99%: only 7 of 812 healthy controls scored positive. In addition, CancerSEEK localized the cancer to a small number of anatomic sites in a median of 83% of the patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available